You are here

Bristol-Myers vulnerable to takeover after setback in cancer drug

It sheds US$37b in market value after losing gamble on a clinical trial of its Opdivo drug

Washington

AT a Chicago convention jammed with thousands of doctors in 2015, a buzz of excitement rippled through the hall as a researcher revealed data showing that a Bristol-Myers Squibb Co drug cocktail had remarkable success in fighting a deadly form of skin cancer.

It was a

sentifi.com

Market voices on:

Powered by GET.comGetCom